North America Injectable Drug Delivery Market 2017-2024 - Market is Expected to Reach $354.5 Billion by 2024 $154.0 Billion in 2016

Dublin, Aug. 17, 2017 -- The "North America Injectable Drug Delivery Market - Industry Trends and Forecast to 2024" report has been added to Research and Markets' offering.

The North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024.

Synopsis:

• North America injectable drug delivery market is segmented on the basis of type, applications, usage pattern, mode of administration, end user, and country.
• On the basis of applications, the injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.
• Based on indications, the market is segmented into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis, and others.
• The North America Injectable Drug Delivery Market is segmented into 3 major countries such as U.S., Canada, Mexico

Key Topics Covered:

1. Introduction
1.1. Overview of North America Injectable Drug Delivery Market
1.2. Currency and Pricing
1.3. Limitation
1.4. Markets Covered

2. Market Segmentation
2.1. Markets Covered
2.2. Geographic Scope
2.3. Years Considered for the Study
2.4. Currency and Pricing
2.5. Research Methodology
2.6. Primary Interviews With Key Opinion Leaders
2.7. Secondary Sources
2.8. Assumptions

3. Market Overview
3.1. Drivers
3.1.1. Rising Cases of Chronic Diseases
3.1.2. Rising Demand of Self-Injection Devices
3.1.3. Growth of Biologics Market
3.1.4. Technological Advancements and Innovations in Drug Delivery Market
3.2. Restraints
3.2.1. Needlestick Injuries and Infections
3.2.2. High Cost of Development
3.2.3. Strict Regulatory Framework
3.3. Opportunity
3.3.1. Increasing Demand for Generic and Biosimilar Drugs
3.3.1.1. Generics
3.3.1.2. Biosimilars
3.3.2. Increasing Demand for Contraceptive Injectables
3.3.3. Increasing Demand for Self-Administration of Drugs
3.4. Challenges
3.4.1. Alternative Route of Drug Administration
3.4.2. Product Recall
3.4.3. Stability of Products
3.4.4. Sterility of Injections

4. Executive Summary

5. Premium Insights

6. North America Injectable Drug Delivery Market, Regulatory
6.1. Overview
6.2. U.S. Fda Approval

7. North America Injectable Drug Delivery Market, by Type
7.1. Overview
7.2. Injectable Drug Delivery Devices
7.2.1. Conventional Injection Devices
7.2.2. Self Injection Devices
7.2.2.1. Needle Free Injectors (Nfi)
7.2.2.2. Auto Injectors
7.2.2.3. Pen Injectors
7.2.2.4. Wearable Injectors
7.3. Injectable Drug Delivery Formulation
7.3.1. Conventional Drug Delivery Formulations
7.3.1.1. Solutions
7.3.1.2. Reconstituted/Lyophilized Formulations
7.3.1.3. Suspensions
7.3.1.4. Emulsions
7.3.2. Novel Drug Delivery Formulations
7.3.2.1. Colloidal Dispersions
7.3.2.2. Microparticles
7.3.2.3. Long Acting Injection Formulation

8. North America Injectable Drug Delivery Market,
By Application
8.1. Overview
8.2. North America Injectable Drug Delivery Market, by Application
8.3. Hormonal Disorders
8.3.1. Injectable Drugs for Diabetes
8.3.2. Injectable Drugs for Anemia
8.3.3. Injectable Drugs for Reproductive Health Disease
8.3.4. Injectable Drugs for Antithrombotic/Thrombolytic Therapy
8.3.5. Injectable Drugs for Osteoporosis
8.3.6. Injectable Drugs for Growth Hormone Disorders (Ghd)
8.4. Oncology
8.5. Autoimmune Diseases
8.5.1. Injectable Drugs for Rheumatoid Arthritis
8.5.2. Injectable Drugs for Multiple Sclerosis
8.5.3. Injectable Drugs for Crohn's Diseases
8.5.4. Injectable Drugs for Psoriasis
8.5.5. Injectable Drugs for Other Autoimmune Diseases
8.6. Orphan Disease
8.7. Other Applications
8.7.1. Injectable Drugs for Pain Management
8.7.2. Injectable Drugs for Allergy Treatment
8.7.3. Injectable Drugs for Aesthetic Treatments
8.7.4. Injectable Drugs for Hepatitis C
8.7.5. Injectable Drugs for Hemophilia

9. North America Injectable Drug Delivery Market,
By Usage Pattern
9.1. Overview
9.2. Curative Care
9.3. Immunizations
9.4. Other Usage Pattern

10. North America Injectable Drug Delivery Market,
By Mode of Administration
10.1. Overview
10.2. Skin
10.3. Circulatory/ Muskoskeletal
10.4. Organs
10.5. Central Nervous System

11. North America Injectable Drug Delivery Market, by End User
11.1. Overview
11.2. Hospitals and Clinics
11.3. Home Healthcare Settings
11.4. Research Laboratories
11.5. Pharmaceutical and Biotechnological Companies
11.6. Other End Users

12. North America Injectable Drug Delivery Market,
By Distribution Channel
12.1. Overview
12.1.1. Hospital Pharmacy
12.1.2. Pharmacy Stores
12.1.3. Direct Tender
12.1.4. Online Pharmacy

13. North America Injectable Drug Delivery Market, by Country
13.1. Overview
13.1.1. U.S. Injectable Drug Delivery Market
13.1.2. Canada Injectable Drug Delivery Market
13.1.3. Mexico Injectable Drug Delivery Market

14. North America Injectable Drug Delivery Market,
Company Share
14.1. Company Share Analysis: North America

15. Company Profiles

• Baxter International Inc.
• Becton
• Dickinson and Company
• Gerresheimer AG
• Pfizer Inc.
• Schott AG
• Alkermes Plc.
• Eli Lilly and Company
• Sandoz
• Terumo Corporation
• Teva Pharmaceuticals Industries Ltd.
  

For more information about this report visit https://www.researchandmarkets.com/research/d4blvq/north_america

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Infusions and Injectables